Adapting the innate immune system to develop long-lived vaccines to bacterial pathogens

• DOI: 10.4049/jimmunol.198.supp.73.7
• Publication Date: 2023-01-01T11:21:01Z
• Authors: Michael Super; Edward Doherty; Mark Cartwright; Alexander Stafford; Omar Ali; Des White; Amanda Graveline; Frank Urena; Chloe MacDonald; Alexandre Dinis; Shannon Duffy; Benjamin Duckless; Benjamin Seiler; Donald Ingber; David Mooney
• Keywords: 0301 basic medicine; 03 medical and health sciences; 3. Good health

Abstract There is an urgent need to develop vaccines against bacteria due the rise of Multi-drug resistant (MDR & XDR) organisms. To date, it has been difficult produce protective bacterial pathogens; there a danger outgrowth fast growing attenuated strains while polysaccharide cell walls are poorly immunogenic and subunit ineffective, generating TI (T-independent) immune responses, characterized by low affinity, short lived, non-class switched IgM antibodies. We developing technologies for in mice multiple pathogen species, including bacterial; MDR E. coli, MRSA, MTb LAM, Viral; HIV gp120, parasitic; P. falciparum fungal; C. albicans. capture pathogens using FcMBL Opsonin technology (which binds more than 90 different species), present killed modulating biomaterial system. This lyophilized product provides long-lasting protection with single dose through novel self-boosting mechanism action. Our can protect coli which lethal within 12 hours. have raised antibodies titers sustained beyond days (to date) vaccination (the system demonstrated 1 year other indications). Using this opsonin technology, be captured from blood tissues one animal used vaccinate animals.